A non-blind, randomized, parallel group comparative trial to study the efficacy and safety of Mao-to in the treatment of influenza.

Phase 4

• Conditions: Influenza Type A and Type B

• Registration Number: JPRN-UMIN000001653
• Lead Sponsor: Fukuoka University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-23
• Study Completion: 2009-05-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1) Administration of Kampo medicine or any respiratory medication within 3 days prior to registration. 2) Administration of influenza vaccination within 2 weeks prior to registration. 3) Serious disease complication including, but not limited to: liver, kidney, heart, lung, circulatory, or metabolic disorder. 4) Suspicion of supervening bacterial infection of the respiratory tract. 5) History of drug allergies. 6) Females who are pregnant, lactating or planning pregnancy. 7) Administration of another investigational drug within 4 weeks prior to registration or during the study period, or planned participation in another study. 8) Contraindications to acetaminophen (peptic ulcer, aspirin-induced asthma, acetaminophen hypersensitivity). 9) Subjects who are unfit for the study as judged by the research director, research staff, or others (referred to as "research director and team")

Study & Design

• Study Type: Interventional
• Study Design: Not specified